MediciNova achieves target enrolment in SEANOBI-ALS study of MN-166

MediciNova has achieved the target enrolment of 200 patients in the SEANOBI-ALS clinical study, evaluating MN-166 (ibudilast) for ALS. MediciNova has indicated that final follow-ups are expected to be completed in early 2027. MN-166 is being investigated for various neuroinflammatory and neurodegenerative conditions, including ALS. Credit: David Herraez Calzada / Shutterstock.com. MediciNova has achieved the target enrolment of 200 patients in the SEANOBI-ALS clinical study, evaluating MN-166 (ibudilast) for amyotrophic lateral sclerosis (ALS). The SEANOBI programme offers expanded access to MN-166 for people with ALS who do not qualify for ongoing randomised clinical trials. LOA and PTSR Model Navicixizumab…

Source: Clinical Trials Arena